dc.creatorGuerrero, Laura
dc.creatorSangro, Bruno
dc.creatorAmbao, Veronica Ana
dc.creatorGranero, José Ignacio
dc.creatorRamos Fernández, Antonio
dc.creatorParadela, Alberto
dc.creatorCorrales, Fernando J.
dc.date.accessioned2022-09-28T10:10:39Z
dc.date.accessioned2022-10-15T02:56:41Z
dc.date.available2022-09-28T10:10:39Z
dc.date.available2022-10-15T02:56:41Z
dc.date.created2022-09-28T10:10:39Z
dc.date.issued2021-12-13
dc.identifierGuerrero, Laura; Sangro, Bruno; Ambao, Veronica Ana; Granero, José Ignacio; Ramos Fernández, Antonio; et al.; Monitoring one-carbon metabolism by mass spectrometry to assess liver function and disease; Servicio Publicaciones Universidad Navarra; Journal of Physiology and Biochemistry; 78; 1; 13-12-2021; 229-243
dc.identifier1138-7548
dc.identifierhttp://hdl.handle.net/11336/170708
dc.identifierCONICET Digital
dc.identifierCONICET
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/4337437
dc.description.abstractPrecision medicine promises to overcome the constraints of the traditional “one-for-all” healthcare approach through a clear understanding of the molecular features of a disease, allowing for innovative and tailored treatments. State-of-the-art proteomics has the potential to accurately explore the human proteome to identify, quantify, and characterize proteins associated with disease progression. There is a pressing need for informative biomarkers to diagnose liver disease early in its course to prevent severe disease for which no efficient treatment is yet available. Here, we propose the concept of a cellular pathway as a functional biomarker, whose monitorization may inform normal and pathological status. We have developed a standardized targeted selected-reaction monitoring assay to detect and quantify 13 enzymes of one-carbon metabolism (1CM). The assay is compliant with Clinical Proteomics Tumor Analysis Consortium (CPTAC) guidelines and has been included in the protein quantification assays that can be accessed through the assay portal at the CPTAC web page. To test the feasibility of the assay, we conducted a retrospective, proof-of-concept study on a collection of liver samples from healthy controls and from patients with cirrhosis or hepatocellular carcinoma (HCC). Our results indicate a significant reconfiguration of 1CM upon HCC development resulting from a process that can already be identified in cirrhosis. Our findings indicate that the systematic and integrated quantification of 1CM enzymes is a promising cell function-based biomarker for patient stratification, although further experiments with larger cohorts are needed to confirm these findings.
dc.languageeng
dc.publisherServicio Publicaciones Universidad Navarra
dc.relationinfo:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.1007/s13105-021-00856-3
dc.relationinfo:eu-repo/semantics/altIdentifier/url/https://link.springer.com/article/10.1007/s13105-021-00856-3
dc.rightshttps://creativecommons.org/licenses/by/2.5/ar/
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectBIOLOGY AND DISEASE HUMAN PROTEOME PROJECT (B/D-HPP)
dc.subjectCPTAC
dc.subjectLIVER CANCER
dc.subjectLIVER INJURY
dc.subjectONE-CARBON METABOLISM
dc.subjectSRM
dc.subjectTARGETED PROTEOMICS
dc.titleMonitoring one-carbon metabolism by mass spectrometry to assess liver function and disease
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:ar-repo/semantics/artículo
dc.typeinfo:eu-repo/semantics/publishedVersion


Este ítem pertenece a la siguiente institución